Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Work In Process: 2017-2025

Historic Work In Process for Adma Biologics (ADMA) over the last 6 years, with Sep 2025 value amounting to $44.5 million.

  • Adma Biologics' Work In Process fell 16.82% to $44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year decrease of 16.82%. This contributed to the annual value of $61.6 million for FY2024, which is 24.22% up from last year.
  • Per Adma Biologics' latest filing, its Work In Process stood at $44.5 million for Q3 2025, which was up 3.04% from $43.2 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Work In Process ranged from a high of $62.1 million in Q1 2023 and a low of $43.2 million during Q2 2025.
  • For the 3-year period, Adma Biologics' Work In Process averaged around $53.3 million, with its median value being $53.5 million (2024).
  • In the last 5 years, Adma Biologics' Work In Process soared by 94.66% in 2021 and then dropped by 21.60% in 2025.
  • Over the past 5 years, Adma Biologics' Work In Process (Quarterly) stood at $59.0 million in 2021, then decreased by 4.74% to $56.2 million in 2022, then decreased by 11.66% to $49.6 million in 2023, then increased by 24.22% to $61.6 million in 2024, then declined by 16.82% to $44.5 million in 2025.
  • Its Work In Process was $44.5 million in Q3 2025, compared to $43.2 million in Q2 2025 and $49.8 million in Q1 2025.